MorphoSys AG (MOR) News Headlines

▮ More

Date

Headline

1/9/2023 1:44:49 AM MorphoSys Expects Topline Data From Phase 3 MANIFEST-2 Study Of Pelabresib In Myelofibrosis In Early 2024

1/5/2023 6:21:15 AM MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales Of $89.4 Mln

12/20/2022 8:19:53 PM MorphoSys CFO Sung Lee To Step Down In March 2023

12/12/2022 12:47:45 AM MorphoSys Announces Longer-term Phase 2 Results On Pelabresib In Myelofibrosis

12/12/2022 12:04:36 AM MorphoSys Presents New Longer-term Phase 2 Results On Pelabresib In Myelofibrosis At ASH

12/6/2022 8:15:36 PM MorphoSys, Novartis To Research & Commercialize Pre-clinical Inhibitors Of Novel Cancer Target

11/16/2022 5:42:55 PM MorphoSys AG Q3 Loss Climbs

11/16/2022 4:06:37 PM MorphoSys Q3 Loss/share EUR 3.60 Vs. Loss EUR 3.30 Year Ago

11/14/2022 7:01:00 AM Pre-market Movers: OPNT, MOR, TRMR, TOI, NKTR…

11/14/2022 1:29:42 AM Genentech : Phase III Studies Of Gantenerumab In Early Alzheimer's Disease Fails To Meet Main Goal

10/21/2022 10:06:34 AM MorphoSys Cuts FY Monjuvi U.S. Net Product Sales Outlook

10/21/2022 9:23:11 AM MorphoSys Sees 2022 Monjuvi U.S. Net Product Sales To Be About $90 Mln

8/3/2022 4:11:03 PM MorphoSys AG Q2 Earnings Summary

7/26/2022 6:54:03 AM MorphoSys Reports Preliminary Q2 Monjuvi U.S. Sales; Updates 2022 Guidance

7/26/2022 6:16:52 AM MorphoSys Preliminary Q2 Monjuvi U.S. Net Product Sales $23.3 Mln/EUR 21.7 Mln

6/15/2022 9:13:53 AM HIBio To Develop, Commercialize MorphoSys' Felzartamab, And TJ210 Outside Of Greater China

6/15/2022 8:43:08 AM I-Mab Partner MorphoSys Announces License Agreements For Felzartamab And TJ210

6/14/2022 9:50:25 PM MorphoSys, HIBio Reach Agreements For Felzartamab And MOR210

6/14/2022 4:09:51 PM MorphoSys And HIBio Enter Into Equity Participation And License Agreements For Felzartamab And MOR210

6/10/2022 3:30:46 AM MorphoSys Presents Data From Multiple Analyses Of MANIFEST Study

Morphosys Ag (MOR)